Join Monica Richey, NP, with 20+ years of experience in Rheumatology, as she breaks down the latest 2024 ACR guidelines for monitoring lupus nephritis. Learn the best practices for urine testing, protein-creatinine ratios, and medication adjustments to ensure optimal patient care.

She emphasizes the importance of regular urine tests, protein-creatinine ratio checks, and full blood panels to track disease progression and adjust treatment as needed. Monitoring should be done at every visit, especially after starting new medications, with particular attention to trends in protein levels to guide treatment decisions. Additionally, Monica highlights the critical role of medication adherence, noting that treatment failure is sometimes due to missed doses rather than ineffective therapy. By consistently tracking lab results and confirming patient compliance, healthcare providers can optimize lupus nephritis management.

For more expert insights, visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

This video is a must-watch for rheumatologists, nephrologists, nurse practitioners, and lupus patients looking to stay updated on evidence-based monitoring strategies.

Join Audrey Gibson, PA-C, a seasoned rheumatology provider at the Arthritis Center of North Georgia with 18 years of clinical experience, as she explores the question: Can patients recapture their response to IL-17 inhibitor therapy after an interruption or discontinuation?

In this discussion, Audrey reviews key findings from a pivotal clinical trial by Landewé et al., which examined the recapture and retreatment rates of Ixekizumab in axial spondyloarthritis (axSpA) after therapy withdrawal. The randomized, placebo-controlled study followed 155 patients with axSpA who achieved remission and were either continued on Ixekizumab or switched to placebo.

Key results from the study revealed that 96% of patients who withdrew to placebo were able to recapture low disease activity upon retreatment, while 71% regained inactive disease status. These findings offer critical insights for rheumatology providers counseling patients who experience therapy interruptions due to illness, infection, surgery, or personal choice.

This discussion provides a valuable clinical perspective on IL-17 inhibitor retreatment strategies and helps answer common patient concerns about treatment withdrawal and re-initiation.

For more expert insights on IL-17 inhibition and axial spondyloarthritis management, visit RhAPP.org or explore additional educational content on the RhAPP ACE App.

In this expert-led video, Stacey Johnson, NP-C, from the Montana Arthritis Center, breaks down the 2024 ACR Guidelines for Lupus Nephritis and highlights key treatment strategies—including hydroxychloroquine dosing, steroid pulse and taper regimens, and the role of triple therapy. Learn how to tailor treatment for Class III, IV, and V Lupus Nephritis using combinations like mycophenolate, belimumab, calcineurin inhibitors, and low-dose cyclophosphamide.

These updated recommendations emphasize precision and safety, focusing on minimizing steroid exposure while maximizing disease control through multi-targeted immune therapy.

For more rheumatology insights and clinical updates, visit the Content Rheum at RhAPP.org or download the RhAPP ACE app.

#LupusNephritis #ACRGuidelines #RheumatologyEducation #SteroidTapering #Belimumab #Hydroxychloroquine #Mycophenolate #TripleTherapy #AutoimmuneDisease #RhAPP #ContentRheum